Age-dependent SMN expression in disease-relevant tissue and implications for SMA treatment
Daniel M. Ramos(Bial (Portugal)), Charlotte J. Sumner(Johns Hopkins University), Sergey Paushkin(NKT Therapeutics (United States)), Thomas O. Crawford(Johns Hopkins University), Ian Waters(Sidney Kimmel Comprehensive Cancer Center), Nikolai A. Naryshkin(PTC Therapeutics (United States)), Daniel A. Norris(Ionis Pharmaceuticals (United States)), Frank Rigo(Ionis Pharmaceuticals (United States)), Shannon J. Taylor(Portage College), Constantin d’Ydewalle(Janssen (Belgium)), Nikhil Gupte(Johns Hopkins University), Pamela J. Snyder(The Ohio State University), Amal Dakka(PTC Therapeutics (United States)), John Matson(Ionis Pharmaceuticals (United States)), Phillip G. Zaworski(Portage College), Kathryn J. Swoboda(Massachusetts General Hospital), C. Frank Bennett(Pennsylvania State University), Christine L. Hatem(Johns Hopkins University), Vijayalakshmi Gabbeta(PTC Therapeutics (United States)), Thomas W. Prior(Goethe University Frankfurt), Stéphanie Klein(Ionis Pharmaceuticals (United States)), David Valdivia(Johns Hopkins University)
Cited by 190
Related Papers
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
|Cell Metabolism|2006|2.1k
Myoblast Transfer in the Treatment of Duchenne's Muscular Dystrophy
|New England Journal of Medicine|1995|522
Mutations in the skeletal muscle α-actin gene in patients with actin myopathy and nemaline myopathy
|Nature Genetics|1999|401